Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Sim, S; McCaughan, G; Zannettino, A; Ho, PJ; Joshua, D; Talaulikar, D; Mollee, P; Prince, HM; Spencer, A; Harrison, S; Lee, C; Augustson, B; Kalff, A; Ling, S; Weber, N; Yong, A; Quach, H

Author(s): Sim, S; McCaughan, G; Zannettino, A; Ho, PJ; Joshua, D; Talaulikar, D; Mollee, P; Prince, HM; Spencer, A; Harrison, S; Lee, C; Augustson, B; Kalff, A; Ling, S; Weber, N; Yong, A; Quach, H;
Details: Publication Year 2026-03,Volume 56,Issue #3,Page 457-464
Journal Title: Internal Medicine Journal
Publication Type: Guideline
Abstract: Patients with newly diagnosed multiple myeloma and considered transplant ineligible (TIE) because of age, frailty and/or comorbidities now have access to highly effective therapies that can achieve deep and/or durable remission. TIE patients are a highly heterogeneous population whose biological and chronological age can vary substantially. The treatment of these patients can be challenging in clinical practice and requires a frailty-adapted, individualised approach with an emphasis on treatment deliverability and tolerability to optimise patient outcomes. Here, we summarise recommendations for TIE patients, including pre-treatment considerations, induction and maintenance therapies, and supportive care management.
Publisher: Wiley
Keywords: Humans; *Multiple Myeloma/therapy/diagnosis/epidemiology; Australia/epidemiology; Transplantation, Autologous; *Hematopoietic Stem Cell Transplantation; Advisory Committees/standards; frailty; multiple myeloma; transplant ineligible; treatment
Department(s): Haematology
Publisher's Version: https://doi.org/10.1111/imj.70329
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2026-01-23 05:48:31

Last Modified: 2026-04-07 03:20:36